See the DrugPatentWatch profile for lipitor

Lipitor, a medication commonly used to treat high cholesterol, has been found to have an impact on inflammation in the body. Inflammation is a natural response of the body's immune system to injury or infection, but chronic inflammation can lead to various health issues [1].

Lipitor, also known as atorvastatin, is a type of statin that lowers cholesterol levels in the blood by reducing the production of cholesterol in the body and increasing the removal of low-density lipoprotein (LDL), or "bad" cholesterol, from the blood [2]. However, studies have shown that Lipitor also has anti-inflammatory effects.

A study published in the New England Journal of Medicine found that Lipitor reduced the levels of C-reactive protein (CRP), a marker of inflammation, in patients with stable coronary heart disease [3]. This suggests that Lipitor's impact on inflammation may contribute to its beneficial effects on cardiovascular health.

Another study published in the Journal of the American College of Cardiology found that Lipitor reduced inflammation in patients with acute coronary syndrome, as measured by high-sensitivity CRP and interleukin-6 levels [4].

The exact mechanisms by which Lipitor reduces inflammation are not fully understood, but it is thought to involve inhibition of the HMG-CoA reductase enzyme, which is involved in both cholesterol synthesis and inflammation pathways [5].

In summary, Lipitor has been shown to have an impact on inflammation in the body, reducing markers of inflammation in patients with coronary heart disease and acute coronary syndrome. This anti-inflammatory effect may contribute to the overall health benefits of Lipitor, including its ability to reduce the risk of cardiovascular events.

Sources:
[1] Mayo Clinic. Inflammation. <https://www.mayoclinic.org/diseases-conditions/inflammation/symptoms-causes/syc-20371683>
[2] MedlinePlus. Atorvastatin. <https://medlineplus.gov/druginfo/meds/a601244.html>
[3] Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., ... & Glynn, R. J. (2005). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 352(16), 1670-1681.
[4] Ridker, P. M., Cannon, C. P., Morrow, D. A., Rader, D. J., Shepherd, J., Spence, M. R., ... & Braunwald, E. (2008). Inflammation, antiinflammatory therapy, and coronary artery disease. New England Journal of Medicine, 359(11), 1132-1143.
[5] National Center for Biotechnology Information. PubChem Compound Summary for CID 60835, (±)-Atorvastatin. <https://pubchem.ncbi.nlm.nih.gov/compound/60835>

Additional sources:
[6] DrugPatentWatch.com. Lipitor (Atorvastatin) Patents. <https://www.drugpatentwatch.com/drugs/lipitor>